Filter by Category: Antimicrobial Surveillance
Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American Medical Centers (2003).
Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American Medical Centers (2003). by Sader HS, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 53 (4): 329-332
An overview of the Meropenem Yearly Susceptibility Test Information Collection (Mystic) Program: 1997-2004.
An overview of the Meropenem Yearly Susceptibility Test Information Collection (Mystic) Program: 1997-2004. by Jones RN, Mendes C, Turner PJ and Masterton R published in Diagn. Microbiol. Infect. Dis. 2005; 53 (4): 247-256
Antimicrobial activity of doripenem (S-4661): A global surveillance report (2003).
Antimicrobial activity of doripenem (S-4661): A global surveillance report (2003). by Fritsche TR, Stilwell MG and Jones RN published in Clin. Microbiol. Infect. 2005; 11 (12): 974-984
Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. by Sader HS, Jones RN, Dowzicky MJ and Fritsche TR published in Diagn. Microbiol. Infect. Dis. 2005; 52 (3):203-208
Trends in linezolid susceptibility patterns: Report from the 2002 – 2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.
Trends in linezolid susceptibility patterns: Report from the 2002 – 2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program. by Anderegg TR, Sader HS, Fritsche TR, Ross JE and Jones RN published in Int. J. Antimicrob. Agents 2005; 26 (1): 13-21
Trends in linezolid susceptibility patterns in 2002: Report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program.
Trends in linezolid susceptibility patterns in 2002: Report from the worldwide Zyvox Annual Appraisal of Potency and Spectrum Program. by Ross JE, Anderegg TR, Sader HS, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 52 (1): 53-58
Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs.
Integrating Escherichia coli antimicrobial susceptibility data from multiple surveillance programs. by Stelling JM, Travers K, Jones RN, Turner PJ, O’Brien TF and Levy SB published in Emerg. Infect. Dis. 2005; 11 (6): 873-882
Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American Medical Centres.
Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American Medical Centres. by Gales AC, Sader HS, Jones RN published in Clin. Microbiol. Infect. 2005; 11 (2): 95-100
Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide.
Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide. by Sader HS, Streit JM, Fritsche TR, Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 50 (3): 201-204
Surveillance in Taiwan using molecular epidemiology for extended-spectrum beta-lactamase-rroducing Klebsiella pneumoniae.
Surveillance in Taiwan using molecular epidemiology for extended-spectrum beta-lactamase-producing Klebsiella pneumoniae. by Yu W-L, Winokur PL, Jones RN and Sader HS published in Infect. Control Hosp. Epidemiol. 2004; 25 (10): 812-818
Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: Report of year five (2003).
Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: Report of year five (2003). by Rhomberg PR, Jones RN, Sader HS, Fritsche TR published in Diagn. Microbiol. Infect. Dis. 2004; 49 (4): 273-281
Determination of epidemic clonality among multi-drug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003).
Determination of epidemic clonality among multi-drug-resistant strains of Acinetobacter spp. and Pseudomonas aeruginosa in the MYSTIC Programme (USA, 1999-2003). by Jones RN, Deshpande L, Fritsche TR, Sader HS published in Diagn. Microbiol. Infect. Dis. 2004; 49 (3): 211-216
Antibiotic resistance in hospitalized patients: MYSTIC Program (1999-2002).
Antibiotic resistance in hospitalized patients: MYSTIC Program (1999-2002). by Rhomberg PR, Fritsche TR, Sader HS, Jones RN published in Antibiot. Clin. 2003; 7 (Suppl 2): 2-7
Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001).
Antimicrobial usage and resistance trend relationships from the MYSTIC Programme in North America (1999-2001). by Mutnick AH, Rhomberg PR, Sader HS, Jones RN published in J. Antimicrob. Chemother. 2004; 53 (2): 290-296
Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: Report of the 2001 data from 15 United States medical centres.
Results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme: Report of the 2001 data from 15 United States Medical Centres. by Rhomberg PR, Jones RN, Sader HS and MYSTIC Programme Study Group published in Int. J. Antimicrob. Agents 2004; 23 (1): 52-59
Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: Report from the MYSTIC Program (2002) in North America.
Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: Report from the MYSTIC Program (2002) in North America. by Rhomberg PR, Jones RN and The MYSTIC Program (USA) Study Group published in Diagn. Microbiol. Infect. Dis. 2003; 47 (1): 365-372
Comparative antimicrobial potency and spectrum of activity for meropenem and nine comparator agents: Report from the United States MYSTIC Program Surveillance Study in 2002. Abstr P1040.
Comparative antimicrobial potency and spectrum of activity for meropenem and nine comparator agents: Report from the United States MYSTIC Program Surveillance Study in 2002. Abstr P1040. by Rhomberg PR, Mutnick AH, Jones RN published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 243
Relationships between susceptibility of Pseudomonas aeruginosa and hospital- and patient-specific variables. Report from the Antimicrobial Resistant Rate Epidemiology Study Team (ARREST Program). Abstr. P1037.
Relationships between susceptibility of Pseudomonas aeruginosa and hospital- and patient-specific variables. Report from the Antimicrobial Resistant Rate Epidemiology Study Team (ARREST Program). Abstr. P1037. by Bhavnani SM, Hammel JP, Ambrose PG, Forrest A, Rubino CM and Jones RN published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): S242-S243
Relationships between susceptibility of Streptococcus pneumoniae and hospital- and patient-specific variables. Report from the Antimicrobial Resistance Rate Epidemiology Study Team (ARREST Program). Abstr. P1036.
Relationships between susceptibility of Streptococcus pneumoniae and hospital- and patient-specific variables. Report from the Antimicrobial Resistance Rate Epidemiology Study Team (ARREST Program). Abstr. P1036. by Bhavnani SM, Hammel JP, Forrest A, Ambrose PG and Jones RN published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 242
Relationships between susceptibility of Enterobacter spp. and hospital- and patient-specific variables. Report from the Antimicrobial Resistance Rate Epidemiology Study Team (ARREST Program).
Relationships between susceptibility of Enterobacter spp. and hospital- and patient-specific variables. Report from the Antimicrobial Resistance Rate Epidemiology Study Team (ARREST Program). by Bhavnani SM, Hammel JP, Forrest A, Ambrose PG and Jones RN published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 241-242
Pharmacokinetics-pharmacodynamics of cefepime and piperacillin/tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum ß-lactamases: Report from the ARREST Program.
Pharmacokinetics-pharmacodynamics of cefepime and piperacillin/tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum ß-lactamases: Report from the ARREST Program. by Ambrose PG, Bhavnani SM and Jones RN published in Antimicrob. Agents Chemother. 2003; 47 (5): 1643-1646
Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team.
Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against Streptococcus pneumoniae: Report from the Antimicrobial Resistance Rate Epidemiology Study Team. by Jones RN, Rubino CM, Bhavnani SJ and Ambrose PG published in Antimicrob. Agents Chemother. 2003; 47 (1): 292-296
CANCER Resistance Surveillance Program: initial results from hematology-oncology centers in North America.
CANCER Resistance Surveillance Program: initial results from hematology-oncology centers in North America. by Mutnick AH, Kirby JT, Jones RN and CANCER Study Group published in Ann. Pharmacol. 2003; 37 (1): 47-56
A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram-negative bacilli including bacteraemic Salmonella spp.: Intial studies for the MYSTIC Programme in India.
A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram-negative bacilli including bacteraemic Salmonella spp.: Initial studies for the MYSTIC Programme in India. by Jones RN, Rhomberg PR, Varnam DJ and Mathai D published in Int. J. Antimicrob. Agents 2002; 20 (6): 426-431
Age-related trends in pathogen frequency and antimicrobial susceptibility of blood stream isolates in North America.
Age-related trends in pathogen frequency and antimicrobial susceptibility of blood stream isolates in North America. by Diekema DJ, Pfaller MA, Jones RN and The SENTRY Participants Group published in Int. J. Antimicrob. Agents. 2002; 20 (6):412-418
Gatifloxacin Phase IV surveillance trial (TeqCES Study) utilizing 5,000 primary care physician practices: Report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
Gatifloxacin Phase IV surveillance trial (TeqCES Study) utilizing 5,000 primary care physician practices: Report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections. by Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 77-84
Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: Report of the Zyvox®; Antimicrobial Potency Study in Latin America (LA-ZAPS).
Multicenter assessment of the linezolid spectrum and activity using the disk diffusion and Etest methods: Report of the Zyvox®; Antimicrobial Potency Study in Latin America (LA-ZAPS). by LA-ZAPS Study Group, Ballow CH, Biedenbach DJ, Rossi F and Jones RN published in Braz. J. Infect. Dis. 2002; 6 (3): 100-109
Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: Report from the Zyvox® Antimicrobial Potency Study (ZAPS-Europe).
Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: Report from the Zyvox® Antimicrobial Potency Study (ZAPS-Europe). by Bolmstrom A, Ballow CH, Qwarnstrom A, Biedenbach DJ and Jones RN published in Clin. Microbiol. Infect. 2002; 8 (12): 791-800
Emerging antimicrobial resistances among Proteus mirabilis in Europe: Report from the MYSTIC Program (1997-2001).
Emerging antimicrobial resistances among Proteus mirabilis in Europe: Report from the MYSTIC Program (1997-2001). by Mutnick AH, Turner PJ and Jones RN published in J. Chemother. 2002; 14 (3): 253-258
Antimicrobial susceptibility of inducible AmpC β-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000.
Antimicrobial susceptibility of inducible AmpC β-lactamase-producing Enterobacteriaceae from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997-2000. by Pfaller MA and Jones RN published in Int. J. Antimicrob. Agents 2002; 19 (5): 383-388
Ciprofloxacin as broad-spectrum empiric therapy–are fluoroquinolones still viable monotherapeutic agents compared with β-lactams: Data from the MYSTIC Program (US).
Ciprofloxacin as broad-spectrum empiric therapy–are fluoroquinolones still viable monotherapeutic agents compared with β-lactams: Data from the MYSTIC Program (US) by Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2002; 42 (3): 213-215
Antimicrobial resistance in Gram-negative isolates from European intensive care units: Data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme.
Antimicrobial resistance in Gram-negative isolates from European intensive care units: Data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme. by Garcia-Rodriguez JA and Jones RN published in J. Chemother. 2002; 14 (1): 25-32
Skin and soft tissue infections in Latin American medical centers: Four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns.
Skin and soft tissue infections in Latin American medical centers: Four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns. by Sader HS, Jones RN, Silva JB and The SENTRY Participants Group (Latin America) published in Diagn. Microbiol. Infect. Dis. 2002; 44:281-288
Surveillance of antibiotic resistance in European ICUs.
Surveillance of antibiotic resistance in European ICUs. by Hanberger H, Diekema D, Fluit A, Jones R, Struelens M, Spencer R and Wolff M published in J. Hosp. Infect. 2001; 48 (3): 161-176
Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f β-lactamase (SME-1) in the United States: Results from the MYSTIC Programme.
Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f β-lactamase (SME-1) in the United States: Results from the MYSTIC Programme. by Gales AC, Biedenbach DJ, Winokur P, Hacek DM, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (2): 125-127
Three independent yearly analyses of the spectrum and potency of metronidazole: A multicenter study of 1,108 contemporary anaerobic clinical isolates.
Three independent yearly analyses of the spectrum and potency of metronidazole: A multicenter study of 1,108 contemporary anaerobic clinical isolates. by Erwin ME, Fix AM and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (2): 129-132
Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America.
Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. by Diekema DJ, Beach ML, Pfaller MA and Jones RN published in Clin. Microbiol. Infect. 2001; 7 (3): 152-157
Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: Microbiology from the medical office practice environment.
Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: Microbiology from the medical office practice environment. by Pfaller MA, Ehrhardt AF, Jones RN. published in Am. J. Med. 2001; 111 (Suppl 9A): 4S-12S; discussion 36S-38S
Epidemiology of sinusitis in the primary care setting: Results from the 1999 – 2000 respiratory surveillance program.
Epidemiology of sinusitis in the primary care setting: Results from the 1999 – 2000 respiratory surveillance program. by Sokol W. published in Am. J. Med. 2001; 111 (Suppl 9A): 13S-24S
Epidemiology of clinically diagnosed community-acquired pneumonia in the primary care setting: Results from the 1999 – 2000 respiratory surveillance program.
Epidemiology of clinically diagnosed community-acquired pneumonia in the primary care setting: Results from the 1999 – 2000 respiratory surveillance program. by Gotfried MH. published in Am. J. Med. 2001; 111 (Suppl 9A):25S-29S
Antimicrobial susceptibility of quinupristin/dalfopristin tested against Gram-positive cocci from Latin America: Results from the global SMART (GSMART) surveillance study.
Antimicrobial susceptibility of quinupristin/dalfopristin tested against Gram-positive cocci from Latin America: Results from the global SMART (GSMART) surveillance study. by Sader HS, Jones RN, Ballow CH, Biedenbach DJ and Cered RF published in Braz. J. Infect. Dis. 2001; 5 (1): 21-31
Antimicrobial activity of linezolid against Gram-positive cocci isolated in Brazil.
Antimicrobial activity of linezolid against Gram-positive cocci isolated in Brazil. by Sader HS, Gales AC and Jones RN published in Braz. J. Infect. Dis. 2001; 5 (4): 171-176
Antimicrobial resistance trends in medical centers using carbapenems: Report of 1999 and 2000 results from the MYSTIC Program (USA).
Antimicrobial resistance trends in medical centers using carbapenems: Report of 1999 and 2000 results from the MYSTIC Program (USA). by Pfaller MA, Jones RN and Biedenbach DJ published in Diagn. Microbiol. Infect. Dis. 2001; 41 (4): 177-182
Determining the value of antimicrobial surveillance programs.
Determining the value of antimicrobial surveillance programs. by Jones RN and Masterton R published in Diagn. Microbiol. Infect. Dis. 2001; 41 (4): 171-175
Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: Clinical features, molecular epidemiology, and antimicrobial susceptibility.
Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: Clinical features, molecular epidemiology, and antimicrobial susceptibility. by Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP and Seifert H published in Clin. Infect. Dis. 2000; 31 (3): 690-697
Global trends in an antimicrobial resistance surveillance system: Results from the MYSTIC Programme.
Global trends in an antimicrobial resistance surveillance system: Results from the MYSTIC Programme. by Pfaller MA and Jones RN published in Clin. Microbiol. Infect. 2000; 6 (Suppl 1): 74
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: Resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas).
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: Resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas). by Pfaller MA and Jones RN published in J. Antimicrob. Chemother. 2000; 46 (Suppl T2): 25-37
Detection of emerging resistance patterns within longitudinal surveillance systems: Data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection.
Detection of emerging resistance patterns within longitudinal surveillance systems: Data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection. by Jones RN published in J. Antimicrob. Chemother. 2000; 46 (Suppl T2): 1-8
Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2,000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999).
Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2,000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States (1999). by Deshpande LM and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 139-142
A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia.
A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. by Bhavnani SM, Drake JA, Forrest A, Deinhart JA, Jones RN, Biedenbach DJ and Ballow CH published in Diagn. Microbiol. Infect. Dis. 2000; 36 (3): 145-158